Novo Nordisk Terminates $598M Heart Failure Cell Therapy Collaboration with Heartseed Amid Major Restructuring

Novo Nordisk; Heartseed; heart failure; cell therapy; HS-001; collaboration termination; strategic restructuring; Maziar Mike Doustdar; diabetes; obesity; biotechnology

Sanofi axes IGM pact, sparking 80% layoffs at the biotech and facility closures

Sanofi, IGM Biosciences, collaboration termination, biotech layoffs, facility closures, IgM antibodies, immunology, inflammation, oncology